Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026
Emily Bury, Advanced Nurse Practitioner for Thrombosis at St.Vincent’s Healthcare Group, shared a post on LinkedIn:
“A fantastic few days at ISTH 2026 in Paris, with rich learning, inspiring discussions and valuable opportunities to connect with colleagues from around the world.
It was exciting to see women’s health take centre stage, including the launch of the ‘Women’s Health Hub‘—a significant step towards advancing research, education and equitable care for women with thrombosis and bleeding disorders.
Another key highlight was the continued focus on ‘cancer-associated VTE‘, with the ‘API-CAT trial‘ demonstrating that extended treatment with ‘reduced-dose apixaban’ was non-inferior to the full treatment dose for preventing recurrent VTE, while reducing clinically relevant bleeding.
Delighted to attend alongside Tracy Egan of the Irish Heart Foundation – (supporting Thrombosis patients).
Looking forward to bringing insights from ISTH back to support better patient care.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question